RXRX FY 2022 Earnings — Recursion Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RXRXRecursion Pharmaceuticals, Inc.

$2B

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$40M+296.8% YoY

Gross Profit

-$9M-21.7% margin

Operating Income

-$246M-619.3% margin

Net Income

-$239M-603.5% margin

EPS (Diluted)

$-1.36

Cash Flow

Operating Cash Flow

-$84M

Free Cash Flow

-$121M

Stock-Based Comp.

$28M

Balance Sheet

Total Assets

$701M

Total Liabilities

$215M

Stockholders' Equity

$486M

Cash & Equivalents

$550M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$40M	$10M	+296.8%
Gross Profit	-$9M	$10M	-185.9%
Operating Income	-$246M	-$183M	-34.4%
Net Income	-$239M	-$186M	-28.4%